A carregar...
Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma
Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL. We report a patient with relapsed indolent CNSL who fa...
Na minha lista:
| Publicado no: | CNS Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Future Medicine Ltd
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4778415/ https://ncbi.nlm.nih.gov/pubmed/25905905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns.15.3 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|